What will the FDA's decision be on Roflumilast (ARQ-151) by Arcutis Biotherapeutics in June 2026

30-day trend

Analysis

Markets are pricing an 82% likelihood that the FDA approves Roflumilast (ARQ-151), Arcutis Biotherapeutics' topical treatment, by end of June 2026. This high confidence reflects either recent positive clinical data or an advanced stage in the review process, with relatively low odds assigned to outright denial (4%) or no decision within the timeframe (9%). The approval probability would shift materially based on whether the FDA issues a Complete Response Letter citing additional data needs, or if Arcutis withdraws the application. The key resolution event is the FDA's action letter, which typically arrives by the Prescription Drug User Fee Act (PDUFA) deadline. Movement in these prices would signal new information about manufacturing compliance, efficacy data interpretation, or regulatory feedback.

• ›FDA PDUFA action letter deadline in June 2026 is the hard resolution date; any decision after month-end resolves as 'No Decision'
• ›Recent regulatory communications or clinical trial results that would indicate FDA satisfaction with efficacy and safety profile relative to dermatology standards
• ›Manufacturing or chemistry/manufacturing/controls (CMC) issues that could trigger a Complete Response Letter rather than approval
• ›Competitive landscape and unmet need in the indication (atopic dermatitis, plaque psoriasis, or other inflammatory skin condition) may influence expedited review pathway status
• ›Historical approval rates for similar topical immunomodulatory agents and whether ARQ-151 follows typical approval timelines or faces unusual scrutiny

What moved the line

• Jun 20Conditional / Accelerated Approval↑5pp4→9¢ · Kalshi
• Jun 22Full Approval↓4pp80→76¢ · Kalshi
• Jun 25Full Approval↑3pp78→81¢ · Kalshi
• Jun 22Conditional / Accelerated Approval↓3pp9→6¢ · Kalshi
• Jun 20No Decision↓3pp11→8¢ · Kalshi

Recently closed in general

• Will Claire Valdez be victorious in the NY-07 Democratic primary AND Brad Lander be victorious in the NY-10 Democratic primary AND Darializa Avila Chevalier be defeated in the NY-13 Democratic primary for Sep 2026last 69% · 1d
• Will Darializa Avila Chevalier be victorious in the NY-13 Democratic primary AND Alex Bores be defeated in the NY-12 Democratic primary for Sep 2026last 37% · 2d
• Who will win the 2026 D.C. Democratic Mayoral Primarylast 97% · 7d
• Louisiana Democratic Senate Primary Winnerlast 89% · 7d
• Will Databricks' valuation hit __ by December 31?: ↑$180Blast 94% · 7d

These markets stopped trading. Last odds and any captured outcome are shown above — full settlement detail lives at the venue.

How we compute these odds